ABSTRACT
The ofloxacin (OFLX) concentration in serum, saliva and pleural effusion was measured in 12 patients with pleural effusion after oral administration at a dose of 200 mg three times a day (600 mg daily). Three patients had non-small cell lung cancer and the others had pulmonary tuberculosis. The mean OFLX levels in the serum, saliva and pleural effusion at 2 hours after the first administration on day 3 was 3.15 +/- 1.52, 3.36 +/- 2.23 and 2.86 +/- 1.77 micrograms/ml respectively. There was a strong correlation among these concentrations. The OFLX concentration of pleural effusion was predictable from that of saliva. A 3-day oral administration is sufficient to achieve the OFLX level of pleural effusion similar to that of the serum. It is possible that OFLX is effective for pleuritis caused not only by common infectious pathogens but also by Mycobacterium tuberculosis.
Subject(s)
Anti-Infective Agents/pharmacokinetics , Carcinoma, Non-Small-Cell Lung/metabolism , Lung Neoplasms/metabolism , Ofloxacin/pharmacokinetics , Pleural Effusion/metabolism , Saliva/metabolism , Tuberculosis, Pulmonary/metabolism , Administration, Oral , Adult , Aged , Aged, 80 and over , Anti-Infective Agents/administration & dosage , Female , Humans , Male , Middle Aged , Ofloxacin/administration & dosage , Tuberculosis, Pleural/drug therapyABSTRACT
The problems existing in surgical treatment methods for scirrhous carcinoma of the stomach include the following: (1) highly advanced cases are frequent, (2) remnants of carcinoma in the proximal line of resection is frequent, and (3) peritoneal dissemination is frequent. Investigations were made on 76 cases of scirrhous carcinoma of the stomach in the care of our department, and the treatment methods in these cases were as follows: 1) Lymph node dissection: Lymphadenectomy of over R2 is performed. 2) Operative methods: When the cancer lesion is in A, AM, M, or MA, and when the proximal line of resection can be made in the excess of 5 cm from the tumor margin, than a sub-total gastrectomy is performed. For cancer lesions in areas other than the above, and for cancer lesions in the above but when the OW cannot be made to measure over 5 cm, a total gastrectomy is performed. In cases in which the cancer invasion extends beyond EGJ and when non-curative resection factors are absent, then an abdomino-thoracic approach is adopted. 3) Chemotherapy: There was some efficacy among the curative resected cases. Since most of the cases result in peritoneal dissemination, chemotherapy is applied during operation and during the early postoperative period.
Subject(s)
Adenocarcinoma, Scirrhous/surgery , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Gastrectomy/methods , Stomach Neoplasms/surgery , Adenocarcinoma, Scirrhous/drug therapy , Adenocarcinoma, Scirrhous/mortality , Cytarabine/administration & dosage , Fluorouracil/administration & dosage , Gastrectomy/mortality , Humans , Lymph Node Excision/mortality , Lymphatic Metastasis , Mitomycin , Mitomycins/administration & dosage , Postoperative Period , Stomach Neoplasms/drug therapy , Stomach Neoplasms/mortalityABSTRACT
Two patients with recurrent gastrointestinal carcinoma were treated with THP. Partial response was recognized in the local recurrent tumor of one patient and in liver metastasis of a second patient. THP was administered every three weeks at a dose of 60 mg per total body weight intravenously. The total dose of THP achieved was 720 mg in the first patient and 920 mg in the second. Despite the high dosage, neither cardiotoxicity nor alopecia was observed. These results suggest that the administration of THP may be efficacious and safe in the management of patients with recurrent gastrointestinal carcinoma.